1. Home
  2. HTLD vs ANL Comparison

HTLD vs ANL Comparison

Compare HTLD & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartland Express Inc.

HTLD

Heartland Express Inc.

N/A

Current Price

$11.16

Market Cap

1.2B

Sector

Industrials

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$15.99

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HTLD
ANL
Founded
1978
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
998.8M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
HTLD
ANL
Price
$11.16
$15.99
Analyst Decision
Hold
Strong Buy
Analyst Count
6
7
Target Price
$13.20
★ $29.50
AVG Volume (30 Days)
★ 670.2K
181.7K
Earning Date
10-30-2026
08-14-2026
Dividend Yield
★ 0.70%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.07
N/A
Revenue
★ $805,709,000.00
N/A
Revenue This Year
N/A
$243.83
Revenue Next Year
$8.43
N/A
P/E Ratio
$162.14
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.00
$0.88
52 Week High
$16.64
$17.25

Technical Indicators

Market Signals
Indicator
HTLD
ANL
Relative Strength Index (RSI) 35.57 57.29
Support Level $10.67 $14.70
Resistance Level $11.48 $17.10
Average True Range (ATR) 0.34 1.18
MACD -0.01 -0.10
Stochastic Oscillator 11.83 70.03

Price Performance

Historical Comparison
HTLD
ANL

About HTLD Heartland Express Inc.

Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: